Vertex Pharmaceuticals Incorporated (VRTX) News
Follow Vertex Pharmaceuticals Incorporated (VRTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 51 public stories across 24 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Vertex Reports Third-Quarter Revenue of $3.44 Billion, EPS of $2.56
Revenue rose 11.8% year over year to $3.44 billion, while net income fell 39.6% to $653.6 million and diluted EPS declined 39% to $2.56. Cystic fibrosis therapies and newer products supported revenue growth.
EQUITY | Nov 03, 2026, 09:12 PM UTC
M
VRTX Reports Fiscal Q3 Profit and Basic EPS
VRTX reported fiscal third-quarter profit attributable to shareholders of 27.85亿美元, up 0.82% year over year, and basic EPS of 10.98美元.
EQUITY | Nov 03, 2026, 05:29 AM UTC
M
Vertex Pharmaceuticals Raises 2026 Revenue Forecast
Vertex Pharmaceuticals raised its revenue forecast for 2026.
EARNINGS | Nov 02, 2026, 10:14 PM UTC
M
Vertex Closes $10 Billion Crinetics Acquisition
Vertex Pharmaceuticals says the acquisition adds a fourth commercial pillar in rare endocrine diseases. Crinetics' Palsonify generated $10 million in September sales and has captured more than 40% brand share.
MNA | Nov 02, 2026, 09:59 PM UTC
M
Vertex Says Journavx Is US’s Top Branded Oral Pain Drug
Vertex said third-quarter Journavx prescriptions topped 750,000 across hospital and retail settings, up more than 40% sequentially.
EQUITY | Nov 02, 2026, 09:59 PM UTC
M
Vertex Secures Alyftrek Reimbursement in Seven More Countries
Vertex secured reimbursement for its cystic fibrosis therapy Alyftrek in seven additional countries in the third quarter, bringing coverage to 32 nations. International revenue rose 16% to $1.27 billion.
EARNINGS | Nov 02, 2026, 09:59 PM UTC
M
Vertex Raises 2026 Revenue Guidance to $13.15B–$13.25B
Q3 revenue rose 12% year over year to $3.44 billion. Vertex raised its 2026 revenue guidance from $13.1 billion–$13.2 billion.
EARNINGS | Nov 02, 2026, 09:20 PM UTC
M
Vertex Q3 Net Income Falls 40% to $653.6 Million
Vertex Pharmaceuticals reported Q3 2026 net income of $653.6 million, down 40% year over year.
EARNINGS | Nov 02, 2026, 09:20 PM UTC
L
Vertex Pharmaceuticals Reports Third-Quarter EPS of $2.56
EARNINGS | Nov 02, 2026, 09:18 PM UTC
M
Vertex Q3 Revenue Reaches USD 3,440 Million
Vertex Pharmaceuticals reported Q3 revenue of USD 3,440 million, compared with the IBES estimate of USD 3,417 million.
EQUITY | Nov 02, 2026, 09:14 PM UTC
M
Vertex Pharmaceuticals Reports Third-Quarter Adjusted EPS of $4.76
EARNINGS | Nov 02, 2026, 09:13 PM UTC
M
Vertex Reports Third-Quarter 2026 Revenue of $3.44 Billion, Up 12%
Vertex reported total revenue of $3.44 billion for the third quarter of 2026, up 12% from the same quarter in 2025. The supplied text also begins a statement that the company is raising something, but does not specify wh
EQUITY | Nov 02, 2026, 09:06 PM UTC
M
Vertex Reports Third-Quarter 2026 Financial Results
EQUITY | Nov 02, 2026, 09:03 PM UTC
L
Vertex Pharmaceuticals Reports 3Q Net Income of $653.6M
EARNINGS | Nov 02, 2026, 09:01 PM UTC
M
Vertex Says Phase 3 RAINIER Trial Meets Primary Endpoint in IgAN
Povatacicept cut proteinuria 49.8% versus placebo at Week 36 (P<0.0001) and met both secondary endpoints. Vertex’s FDA BLA for accelerated approval is under review, with a Nov. 30, 2026 PDUFA date.
EQUITY | Oct 23, 2026, 05:42 PM UTC
M
Vortex Energy Corp. Acquires Meadows Project Assets in Saskatchewan
Vortex Energy Corp. has completed the acquisition of the Meadows Project assets, located in west-central Saskatchewan. The acquisition includes 100% interest in Subsurface Mineral Permit #SMP273 and associated technical
EQUITY | Oct 01, 2026, 09:01 PM UTC
L
Vertex Pharmaceuticals Price Target Raised to $615.00/Share From $585.00 by UBS
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 06:07 PM UTC
L
Weekly Recap: inaxaplin Phase 2b UACR/UPCR cuts and AMPLITUDE enrollment
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported Phase 2b AMPLIFIED results where inaxaplin 45 mg reduced UACR ~42.7% and UPCR ~44.7% in modest-proteinuria patients with favorable tolerability, modest T2D effec
EQUITY | Sep 28, 2026, 11:04 AM UTC
M
Maze shares jump after Vertex kidney drug study results
Maze Therapeutics shares rose after Vertex reported positive study results for its kidney disease drug, implying strong commercial potential for genetic kidney disease treatments.
EQUITY | Sep 22, 2026, 04:48 PM UTC
M
Vortex Energy to acquire Meadows Project for C$255,000
Vortex Energy entered an agreement to buy the Meadows Project assets in Saskatchewan for C$255,000, assuming required permit obligations. Closing is expected on or about Oct. 1, 2026, subject to customary approvals and c
EQUITY | Sep 17, 2026, 09:34 PM UTC
L
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine f
NEWS | Sep 15, 2026, 11:30 AM UTC
H
VRTX: Upcoming renal and pain launches, pivotal data, and global expansion drive growth outlook
Multiple near-term catalysts are expected, including pivotal renal data, a major IgAN launch, and key readouts in pain and rare diseases. Commercial strategies focus on clinical differentiation, patient access, and globa
EARNINGS | Sep 09, 2026, 09:56 PM UTC
H
VRTX: Upcoming renal and pain catalysts, IgAN launch, and pipeline expansion drive growth outlook
Multiple near-term catalysts include pivotal renal and pain data, a major IgAN launch, and expanded commercial focus following the Crinetics acquisition. Strategic priorities center on broadening the pipeline, accelerati
EARNINGS | Sep 09, 2026, 09:25 PM UTC
L
Vortex Energy plans ground gravity survey at Robinsons River salt project
Vortex Energy Corp. said it plans a targeted ground gravity survey at the Robinsons River Salt Project, advancing priority targets following an August technical study.
EQUITY | Sep 03, 2026, 12:08 PM UTC
L
Vertex Pharmaceuticals price target raised to $665 by Morgan Stanley
Morgan Stanley announced a $665.00 per-share price target for Vertex Pharmaceuticals.
EQUITY | Sep 02, 2026, 10:43 AM UTC
L
News On Crinetics Pharmaceuticals Inc. (CRNX) Now Under VRTX
News On Crinetics Pharmaceuticals Inc. (CRNX) Now Under VRTX
EQUITY | Sep 01, 2026, 09:08 PM UTC
L
Vertex appoints Jonathan Poole CFO; Charles Wagner Jr. becomes COO
Vertex appointed Jonathan Poole as Executive Vice President and Chief Financial Officer, effective January 1, 2027. Charles F. Wagner, Jr. will stop serving as CFO and remain Executive Vice President and Chief Operating
REGULATION | Sep 01, 2026, 08:35 PM UTC
L
Vertex names Jonathan Poole finance chief as Crinetics buy closes
Vertex Pharmaceuticals is appointing Jonathan Poole as CFO in connection with its $10 billion acquisition of Crinetics Pharmaceuticals. Poole is currently senior vice president of finance and will become executive vice p
MNA | Sep 01, 2026, 01:41 PM UTC
L
Vertex completes acquisition of Crinetics Pharmaceuticals
Vertex completed its acquisition of Crinetics Pharmaceuticals and announced an expansion of its executive leadership team.
MNA | Sep 01, 2026, 01:04 PM UTC
L
Vertex Pharmaceuticals names Jonathan Poole CFO, effective Jan. 1
Vertex Pharmaceuticals named Jonathan Poole as chief financial officer, effective Jan. 1.
EQUITY | Sep 01, 2026, 01:04 PM UTC
L
Vertex expands COO role for Charles Wagner overseeing Crinetics integration
Vertex Pharmaceuticals said Charles Wagner will take on an expanded Chief Operating Officer role overseeing the integration of Crinetics.
EQUITY | Sep 01, 2026, 01:04 PM UTC
L
Vertex to Participate in Upcoming September Investor Conferences
Vertex to Participate in Upcoming September Investor Conferences
EQUITY | Aug 26, 2026, 08:00 PM UTC
M
Lupin wins ruling on Vertex cystic fibrosis patents
A ruling has gone in favor of Lupin regarding Vertex patents related to a cystic fibrosis drug, according to TradingView News.
EQUITY | Aug 26, 2026, 08:37 AM UTC
H
Vertex reports second-quarter sales beat and raises FY2026 guidance
Vertex Pharmaceuticals reported second-quarter earnings of $4.73 per share, in line with analyst consensus, and quarterly sales of $3.334 billion, above the $3.232 billion estimate, while raising FY2026 sales guidance.
EARNINGS | Aug 21, 2026, 12:19 PM UTC
L
NOW VRTX UBER - Final Trades on CNBC
NOW VRTX UBER - Final Trades on CNBC
EQUITY | Aug 20, 2026, 05:00 PM UTC
H
VRTX added to US 1 List
VRTX added to BofA's US 1 List
EQUITY | Aug 11, 2026, 10:26 AM UTC
H
VRTX Reports Q2 Revenue of $3.33B
VRTX Q2 revenue rises to $3.33B
EQUITY | Aug 03, 2026, 08:09 PM UTC
H
VRTX Reports Q2 Adj. EPS $4.73
VRTX Q2 earnings miss estimates
EARNINGS | Aug 03, 2026, 08:02 PM UTC
H
Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est
Vertex Pharmaceuticals (NASDAQ: VRTX ) raises FY2026 sales outlook from $12.950 billion-$13.100 billion to $13.100 billion-$13.200 billion vs $13.065 billion estimate.
EARNINGS | Aug 03, 2026, 08:01 PM UTC
H
US Stocks: Implied EPS Movers
Stocks with large implied EPS moves tonight
EARNINGS | Aug 03, 2026, 06:15 PM UTC
H
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
() -- Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday. As of July 6, the NYSE Arca Pharmaceutical Index
RATES | Jul 08, 2026, 03:11 PM UTC
H
What You Missed On Wall Street On Tuesday
Stock indexes retreated amid losses for the heavyweight chip sector, making the Nasdaq the laggard, while the Dow pulled back from a record high reached in morning trading. Memory producers sank even though Samsung poste
GEOPOLITICS | Jul 07, 2026, 08:16 PM UTC
H
Midday Fly By: Wall Street starts coverage of SpaceX with bullish ratings
Stock indexes have retreated amid losses for the heavyweight chip sector and fresh deterioration in the macroeconomic backdrop. The Nasdaq was the laggard, falling over 1%, while the Dow pulled back from a record high re
MACRO | Jul 07, 2026, 03:57 PM UTC
L
Top Midday Stories: Amazon Seeking at Least $25 Billion From US Bond Sale; Fiserv Explores Sale of STAR Debit Network
() -- All three major US stock indexes were down in late-morning trading Tuesday, with the Nasdaq Composite falling 1.4%, as chip stocks sold off and SpaceX (SPCX) debuted on the Nasdaq 100. In company news, Amazon (AMZN
RATES | Jul 07, 2026, 03:43 PM UTC
H
Vertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital
RBC Capital raised the firm's price target on Vertex Pharmaceuticals to $570 from $543 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector
RATES | Jul 07, 2026, 11:27 AM UTC
L
Vertex enters LOI with pan-Canadian Pharmaceutical Alliance for ALYFTREK
Vertex Pharmaceuticals signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, a new triple combination therapy for the treatment of cystic fibrosis in patients aged 6 years and older who ha
EQUITY | Jul 06, 2026, 02:27 PM UTC
L
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
2026-07-03 08:57:20 ET Choosing between Arcutis Biotherapeutics (NASDAQ:ARQT) and
EQUITY | Jul 03, 2026, 01:02 PM UTC
L
Vertex Says Casgevy Label Expansion Opens Treatment to 5,500 More Us Children
On Thursday, the U.S. Food and Drug Administration (FDA) approved an expanded label for Vertex Pharmaceuticals Incorporated ‘s (NASDAQ: VRTX ) Casgevy (exagamglogene autotemcel). The approval allows Casgevy to be used in
GEOPOLITICS | Jul 02, 2026, 12:33 PM UTC
L
Reported Earlier, Vertex Wins FDA Approval Expanding CASGEVY Use To Children As Young As 2 With Severe Sickle Cell Disease Or Beta Thalassem
First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia - - Approximately 5,500 additional children in the U.S. are now
REGULATION | Jul 02, 2026, 07:09 AM UTC
L
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease; The FDA Granted The Approval To Vertex Pharmaceuticals
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease; The FDA Granted The Approval To Vertex Pharmaceuticals
REGULATION | Jul 01, 2026, 09:35 PM UTC
L
IBM, Verizon, Corning And A Health Care Stock On CNBC’s ‘Final Trades’
On CNBC’s “ Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, said Vertex Pharmaceuticals Inc (NASDAQ: VRTX ) is a great name to own in the health care sector. As per t
RATES | Jun 30, 2026, 11:50 AM UTC